C4 Therapeutics (CCCC) vs Galectin Therapeutics (GALT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
C4 Therapeutics (CCCC) has outperformed Galectin Therapeutics (GALT) over the past year, gaining 24.8% versus a loss of 24.1%. Over five years, GALT leads with a +7.4% price change compared with -93.6% for CCCC. Galectin Therapeutics is the larger company by market cap ($365.1 million vs $346.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CCCC | GALT |
|---|---|---|
| Share price | $2.82 | $3.62 |
| Market cap | $346.93M | $365.08M |
| 1-day change | -2.08% | -3.72% |
| YTD return | +47.64% | -12.98% |
| 1-year return | +24.78% | -24.11% |
| 5-year return | -93.57% | +7.42% |
| EPS (TTM) | $-0.91 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.17 | $7.13 |
| 52-week low | $1.69 | $2.03 |
| Distance from 52-week high | -45.45% | -49.23% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +372.70% | +203.87% |
| Average volume | 2.39M | 387.94K |
| Shares outstanding | 123.03M | 100.85M |
| Employees | 104 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CCCC has outperformed GALT by 48.9 percentage points over the past year.
About C4 Therapeutics
CCCC stock →C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 104 employees
About Galectin Therapeutics
GALT stock →Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
CCCC vs GALT FAQ
Which is bigger, C4 Therapeutics or Galectin Therapeutics?
Galectin Therapeutics (GALT) is larger, with a market capitalization of $365.08M compared with $346.93M for C4 Therapeutics (CCCC).
Which stock has performed better over the past year, CCCC or GALT?
CCCC returned +24.78% over the past 12 months, compared with -24.11% for GALT (price return, excluding dividends). Past performance does not predict future results.
Are C4 Therapeutics and Galectin Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for C4 Therapeutics and Biotechnology: Pharmaceutical Preparations for Galectin Therapeutics.